Holen Sie sich die Stockscreener-App
49.19
1.15%
0.56
Vorhandelsmarkt:
49.80
0.61
+1.24%
Schlusskurs vom Vortag:
$48.63
Offen:
$49.07
24-Stunden-Volumen:
1.11M
Relative Volume:
1.58
Marktkapitalisierung:
$2.85B
Einnahmen:
$718.95M
Nettoeinkommen (Verlust:
$-38.55M
KGV:
-71.93
EPS:
-0.6839
Netto-Cashflow:
$45.99M
1W Leistung:
+1.03%
1M Leistung:
-2.56%
6M Leistung:
+4.42%
1J Leistung:
+51.87%
1-Tages-Spanne:
$48.10
$50.55
1-Wochen-Bereich:
$47.17
$50.55
52-Wochen-Spanne:
$29.16
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Firmenname
Supernus Pharmaceuticals Inc
Sektor
Telefon
301-838-2500
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, ZTS, TEVA, HLN, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
49.19 | 2.85B | 718.95M | -38.55M | 45.99M | -0.6839 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.28B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.33B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.76B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 40.70B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.28B | 3.18B | 1.33B | 1.04B | 27.90 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-09 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Fortgesetzt | Jefferies | Buy |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-04-13 | Hochstufung | Jefferies | Hold → Buy |
| 2020-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Fortgesetzt | Jefferies | Hold |
| 2019-11-08 | Herabstufung | Berenberg | Buy → Hold |
| 2019-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-06 | Herabstufung | Jefferies | Buy → Hold |
| 2018-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2018-01-18 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-08 | Hochstufung | Stifel | Hold → Buy |
| 2017-10-19 | Eingeleitet | FBR & Co. | Buy |
| 2017-09-19 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-17 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Eingeleitet | Janney | Neutral |
| 2017-06-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Hochstufung | Jefferies | Hold → Buy |
| 2015-11-05 | Bestätigt | Northland Capital | Outperform |
| 2015-10-28 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Supernus Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Supernus outlines $840M-$870M 2026 revenue outlook as ONAPGO second-supplier filing targeted for Q3 - MSN
Supernus (SUPN) Q1 2026 Earnings Transcript - AOL.com
Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
Earnings call transcript: Supernus Pharmaceuticals Q1 2026 revenue beats forecast - Investing.com Canada
SUPERNUS PHARMACEUTICALS ($SUPN) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative
Four newer Supernus drugs bring in $149.1M as 2026 outlook holds - Stock Titan
[10-Q] SUPERNUS PHARMACEUTICALS, INC. Quarterly Earnings Report - Stock Titan
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat Estimates - Yahoo Finance
Supernus Announces First Quarter 2026 Financial Results - GlobeNewswire
Supernus faces earnings test as Onapgo launch gains traction - Investing.com
Supernus Pharmaceuticals Q1 2026 earnings preview - MSN
How Supernus Pharmaceuticals Inc. (SUPN) Affects Rotational Strategy Timing - Stock Traders Daily
Supernus Pharmaceuticals Earnings: What To Look For From SUPN - Yahoo Finance
[ARS] SUPERNUS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Supernus (NASDAQ: SUPN) sets 2026 virtual meeting on directors, pay and equity plan - Stock Titan
Vanguard (NASDAQ: SUPN) owns 2.9M Supernus shares, 5.03% stake - Stock Titan
Piper Sandler Upgrades Supernus Pharmaceuticals (SUPN) - MSN
Supernus finalizes $350M asset acquisition of Navitor’s SPN-820 - MSN
Vanguard Portfolio Management (NASDAQ: SUPN) holds 3.26M shares, 5.66% - Stock Titan
Supernus Signals Shift on Nasdaq Chart After Results - Kalkine Media
Branded Pharmaceuticals Stocks Q4 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - Yahoo Finance
Pharmaceutical Company Sued For Antitrust Appeals No D&O Coverage Ruling - Mealey's
BofA cuts Supernus Pharmaceuticals stock price target on costs By Investing.com - Investing.com Canada
A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong Recent Shareholder Returns - simplywall.st
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise? - TradingView
(SUPN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
SUPN (Supernus Pharmaceuticals Inc.) delivers 142 percent Q4 2025 EPS surprise, shares rise 4.41 percent today.Shared Buy Zones - Cổng thông tin điện tử Tỉnh Sơn La
Supernus (SUPN) sets May 5 call to discuss Q1 2026 results - Stock Titan
Supernus will detail first-quarter results after markets close May 5 - Stock Titan
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference ... - Caledonian Record
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026 - GlobeNewswire
Supernus Pharmaceuticals (SUPN) Stock: Worth Holding? (Bearish Sentiment) 2026-04-20Community Momentum Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Latest SUPN NewsSupernus Announces First Quarter 2020 Finan... - Stock Titan
Supernus Pharmaceuticals (SUPN) Stock DCF Valuation (Creeps Higher) 2026-04-18Sector Leader - Xã Thanh Hà
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Stock: Trend Direction (Trend Strengthens) 2026-04-18Community Buy Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Q4 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
MACD Signal: Is Supernus Pharmaceuticals Inc part of any major index2026 Year in Review & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Tudor Investment Corp ET AL Invests $1.43 Million in Supernus Pharmaceuticals - National Today
Responsive Playbooks and the SUPN Inflection - Stock Traders Daily
Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Supernus Pharmaceuticals Inc-Aktie (SUPN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Option Exercise |
33.62 |
50,000 |
1,681,205 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Option Exercise |
39.40 |
7,250 |
285,650 |
24,294 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Sale |
50.30 |
50,000 |
2,514,886 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Sale |
50.28 |
50,000 |
2,513,925 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Sale |
49.60 |
7,250 |
359,621 |
17,044 |
0.67%
2.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):